21/04/2014 05:43:55 Free Membership Login

I G I News (AMEX:IG)

DateTimeSource
Headline
04/02/20149:00AMPRNUSIGI Laboratories, Inc. Appoints Damian Finio to Board of Directors
IGI Laboratories, Inc. Appoints Damian Finio to Board of Directors PR Newswire BUENA, N.J., April 2, 2014 BUENA, N.J., April 2, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based generic topical pharmaceutical company, today announced that it has appointed Damian Finio to its Board of Directors. ... More...>>
03/31/20148:00AMPRNUSIGI Laboratories To Present At Needham & Company's 13th Annual Healthcare Conference On April 8, 2014
IGI Laboratories To Present At Needham & Company's 13th Annual Healthcare Conference On April 8, 2014 PR Newswire BUENA, N.J., March 31, 2014 BUENA, N.J., March 31, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the Needham... More...>>
03/12/201412:08PMPRNUSIGI Laboratories, Inc. Announces First ANDA Approval
IGI Laboratories, Inc. Announces First ANDA Approval PR Newswire BUENA, N.J., March 12, 2014 BUENA, N.J., March 12, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received its first approval from the U.S. Food and Drug Administration... More...>>
03/05/20144:05PMPRNUSIGI Laboratories To Present At 26th Annual ROTH Capital Conference On March 10, 2014
IGI Laboratories To Present At 26th Annual ROTH Capital Conference On March 10, 2014 PR Newswire BUENA, N.J., March 5, 2014 BUENA, N.J., March 5, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic pharmaceutical company, will be presenting at the 26th Annual ROTH Conference... More...>>
03/03/20144:05PMPRNUSIGI Laboratories, Inc. Announces Fourteenth ANDA Submission
IGI Laboratories, Inc. Announces Fourteenth ANDA Submission PR Newswire BUENA, N.J., March 3, 2014 BUENA, N.J., March 3, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its first abbreviated new drug application (ANDA... More...>>
02/27/20144:05PMPRNUSIGI Laboratories Announces Fourth Quarter and Year End 2013 Results
IGI Laboratories Announces Fourth Quarter and Year End 2013 Results PR Newswire BUENA, N.J., Feb. 27, 2014 BUENA, N.J., Feb. 27, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the fourth quarter... More...>>
02/14/20144:15PMPRNUSIGI Laboratories To Hold Conference Call For 4th Quarter 2013 Results
IGI Laboratories To Hold Conference Call For 4th Quarter 2013 Results PR Newswire BUENA, N.J., Feb. 14, 2014 BUENA, N.J., Feb. 14, 2014 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call... More...>>
12/31/20131:14PMPRNUSIGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement
IGI Laboratories, Inc. Completes Its Sixth ANDA Filing For 2013 Under Joint Drug Development And Commercialization Agreement PR Newswire BUENA, N.J., Dec. 31, 2013 BUENA, N.J., Dec. 31, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced... More...>>
11/13/20138:00AMPRNUSIGI Laboratories To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013
IGI Laboratories To Present At Oppenheimer 24th Annual Healthcare Conference On December 10, 2013 PR Newswire BUENA, N.J., Nov. 13, 2013 BUENA, N.J., Nov. 13, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based generic topical pharmaceutical company will be presenting at the Oppenheimer 24th... More...>>
11/01/20138:30AMPRNUSIGI Laboratories, Inc. Announces Thirteenth ANDA Submission
IGI Laboratories, Inc. Announces Thirteenth ANDA Submission PR Newswire BUENA, N.J., Nov. 1, 2013 BUENA, N.J., Nov. 1, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its fifth abbreviated new drug application (ANDA... More...>>
11/01/20138:00AMPRNUSIGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate
IGI Laboratories, Inc. Receives Formal US FDA Approval For Site Transfer Of Econazole Nitrate PR Newswire BUENA, N.J., Nov. 1, 2013 BUENA, N.J., Nov. 1, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has received formal approval... More...>>
10/29/20134:00PMPRNUSIGI Laboratories Announces Third Quarter 2013 Results
IGI Laboratories Announces Third Quarter 2013 Results PR Newswire BUENA, N.J., Oct. 29, 2013 BUENA, N.J., Oct. 29, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the third quarter ended September... More...>>
10/04/20139:00AMPRNUSIGI Laboratories To Hold Conference Call For 3rd Quarter 2013 Results
IGI Laboratories To Hold Conference Call For 3rd Quarter 2013 Results PR Newswire BUENA, N.J., Oct. 4, 2013 BUENA, N.J., Oct. 4, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at... More...>>
09/18/20134:00PMPRNUSIGI Laboratories, Inc. Announces Twelfth ANDA Submission
IGI Laboratories, Inc. Announces Twelfth ANDA Submission PR Newswire BUENA, N.J., Sept. 18, 2013 BUENA, N.J., Sept. 18, 2013 /PRNewswire/ -- IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its fourth abbreviated new drug application (ANDA... More...>>
07/25/20134:02PMBWIGI Laboratories Announces 2nd Quarter 2013 Results
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2013. Second Quarter and Year to Date 2013 Highlights Total revenues of $3.8 million in the second quarter of 2013, an increase of 57... More...>>
07/24/20134:35PMBWIGI Laboratories, Inc. Announces Eleventh ANDA Submission
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted its third abbreviated new drug application (ANDA) in 2013 to the U.S. Food and Drug Administration (FDA), which brings the Company’s total number of ANDA submissions to eleven. Jason Grenfell-Gardner... More...>>
07/17/201312:20PMBWIGI Laboratories to Hold Conference Call for 2nd Quarter 2013 Results
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:30 pm ET on Thursday, July 25, 2013 to discuss 2nd quarter 2013 results. The Company invites you to listen to the call by dialing 1-866-515-2909. International... More...>>
06/29/20124:00PMBWIGI Laboratories Announces the Submission of Two More ANDAs
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted two additional abbreviated new drug applications (ANDAs) to the US FDA, bringing the company’s total number of submissions to eight. IGI President and CEO Charlie Moore commented, “We... More...>>
06/05/20128:00AMBWIGI Laboratories Announces the Submission of Sixth ANDA
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based formulation and manufacturing company, today announced that it has submitted an additional abbreviated new drug application (ANDA) to the US FDA, bringing the company’s total number of submissions to six. IGI President and CEO Charlie Moore commented, “Our... More...>>
05/15/20128:00AMBWIGI Laboratories Announces 1st Quarter 2012 Results
IGI Laboratories, Inc. (NYSE Amex: IG), a New Jersey based topical generic drug development and manufacturing company, provided its financial results for the first quarter ended March 31, 2012. First Quarter 2012 Highlights vs. 2011 Total revenues of $1.8 million for Q1 2012, an increase of 16% over same quarter in 2011... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us amex ig140421 05:43